Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow KIORA PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for KIORA PHARMACEUTICALS INC

KPRX KPHMW

KIORA PHARMACEUTICALS INC

About KIORA PHARMACEUTICALS INC

Kiora Pharmaceuticals is a clinical-stage biotech company focused on developing therapies for retinal diseases. Its core assets include KIO-301, a potential vision-restoring small molecule for retinitis pigmentosa, and KIO-104, an anti-inflammatory treatment for retinal conditions. The company advances its products through partnerships, proprietary IP, and clinical trials, targeting underserved ophthalmic markets with innovative, targeted therapies for vision loss and ocular inflammation.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from KIORA PHARMACEUTICALS INC

1
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports $2.42 Million Net Loss in Q1 2026, Increases Cash Reserves

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports $10.8 Million Net Loss and Zero Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports No Revenue and Improved Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports Zero Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports No Revenue and $2.19 Million Net Loss for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports $3.6 Million Net Income in 2024 Fiscal Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
KIORA PHARMACEUTICALS INC Kiora Pharmaceuticals Reports Significant Revenue Growth and Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments